Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.

Objective: Evaluate safety and effectiveness of reduced lenvatinib doses with pembrolizumab in patients with mismatch repair-proficient (MMRp) advanced endometrial cancer.

Methods: In this retrospective cohort study of lenvatinib-pembrolizumab combination therapy, patients were grouped based on initial lenvatinib dose: 20 mg daily (Group 1), less than 20 mg daily (Group 2), and 20 mg daily five days per week (Group 3). The primary outcome was six-month progression-free survival (PFS-6); safety outcomes included incidences of lenvatinib dose discontinuation or reduction due to adverse events (AEs).